Now in a new short wire delivery system, the self-expanding GORE® VIABIL® Short Wire Biliary Endoprosthesis is the only fully-covered metal stent with anti-migration technology proven to minimize the risk of reintervention. Additionally, it offers substantiated evidence in studies that demonstrate sustained long-term patency5,6 :
Demonstrated low migrations - Fully covered anchoring fins
Securely holds the device within the duct to minimize the risk of migration, with a reported 0–1.4% migration rate range outperforming BOSTON SCIENTIFIC WALLFLEX Biliary RX Fully Covered Stent migration rates ranging up to 0–13%.1
Optimal Conformability - Nitinol Wire based stent design
Optimal balance of Radial and Axial force provides the right fit and flexibility to help prevent migration and sludge formation.3,4
Prevents tissue ingrowth and promotes conformability - Durable, non-porous FEP / ePTFE liner
Proven highest patency helps provide a high standard of palliative care for your patients.5,6
Higher primary patency
Clinical performance demonstrates GORE® VIABIL® Biliary Endoprosthesis maintains higher primary patency than the leading competitor at 3, 6, and 12-months.5,6
Improved long-term patency can mean an improved quality of life for patients.
CONMED Biliary Assurance Program
With a 0.2% average reported migration rate, we’re so confident in these outcomes we will replace it* if a migration occurs.
*Subject to terms and conditions, MCM2017139
1W. L. Gore & Associates, Inc. Migration Summary for GORE® VIABIL® Biliary Endoprosthesis and BOSTON SCIENTIFIC WALLFLEX Biliary RX Fully Covered Stent.
Flagstaff, AZ: W. L. Gore & Associates, Inc; 2017. [Literature Summary]. AW0010-EN3.
2W. L. Gore & Associates, Inc. Reduce the risk of reintervention. GORE® VIABIL® Biliary Endoprosthesis Assurance Brochure. Flagstaff, AZ: W. L. Gore & Associates, Inc;
2017. [Flyer]. AW0165-EN1.
3Isayama H, Mukai T, Itoi T, et al. Comparison of partially covered nitinol stents with partially covered stainless stents as a historical control in a multicenter study of distal malignant biliary obstruction: the WATCH study. Gastrointestinal Endoscopy 2012;76(1):84-92.
4Isayama H, Nakai Y, Toyokawa Y, et al. Measurement of radial and axial forces of biliary self-expandable metallic stents. Gastrointestinal Endoscopy 2009;70(1):37-44.
5Kitano M, Yamashita Y, Tanaka K, et al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol. 2013 Nov;108(11):1713-22.
6Krokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, Hatzidakis A. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovascular & Interventional Radiology 2010;33(1):97-106.